ATE490983T1 - Humane antikörper gegen das humane glycoprotein vi und deren verwendung - Google Patents

Humane antikörper gegen das humane glycoprotein vi und deren verwendung

Info

Publication number
ATE490983T1
ATE490983T1 AT02788156T AT02788156T ATE490983T1 AT E490983 T1 ATE490983 T1 AT E490983T1 AT 02788156 T AT02788156 T AT 02788156T AT 02788156 T AT02788156 T AT 02788156T AT E490983 T1 ATE490983 T1 AT E490983T1
Authority
AT
Austria
Prior art keywords
antibody
human
glycoprotein
domain
chain variable
Prior art date
Application number
AT02788156T
Other languages
English (en)
Inventor
Peter A Smethurst
Willem Hendrik Ouwehand
Richard W Farndale
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Application granted granted Critical
Publication of ATE490983T1 publication Critical patent/ATE490983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02788156T 2001-12-20 2002-12-18 Humane antikörper gegen das humane glycoprotein vi und deren verwendung ATE490983T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130543.2A GB0130543D0 (en) 2001-12-20 2001-12-20 Human antibodies and their use
PCT/GB2002/005755 WO2003054020A2 (en) 2001-12-20 2002-12-18 Human antibodies against human glycoprotein vi and their use

Publications (1)

Publication Number Publication Date
ATE490983T1 true ATE490983T1 (de) 2010-12-15

Family

ID=9928080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02788156T ATE490983T1 (de) 2001-12-20 2002-12-18 Humane antikörper gegen das humane glycoprotein vi und deren verwendung

Country Status (8)

Country Link
US (1) US8853368B2 (de)
EP (1) EP1458759B1 (de)
AT (1) ATE490983T1 (de)
AU (1) AU2002352438B2 (de)
CA (1) CA2510745A1 (de)
DE (1) DE60238556D1 (de)
GB (1) GB0130543D0 (de)
WO (1) WO2003054020A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (de) 2002-06-07 2003-12-10 Procorde GmbH Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
CA2606450A1 (en) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
JPWO2007116779A1 (ja) 2006-03-31 2009-08-20 持田製薬株式会社 新規血小板活性化マーカー及びその測定方法
WO2009058326A1 (en) * 2007-10-31 2009-05-07 Otsuka Pharmaceutical Co., Ltd. Uses of a glycoprotein vi (gpvi) inhibitor
EP2411416A1 (de) * 2009-03-24 2012-02-01 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Anti-mesothelin-antikörper
EP2336188A1 (de) * 2009-12-18 2011-06-22 Sanofi-Aventis Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
CA2784498A1 (en) * 2009-12-18 2011-06-23 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2397495A1 (de) * 2010-06-21 2011-12-21 Sanofi Neuartige Antagonistenantikörper und ihre FAB-Fragmente gegen GPVI und Verwendungen davon
US20130217050A1 (en) 2010-09-07 2013-08-22 Mochida Pharmaceutical Co., Ltd. Method for diagnosing alzheimer's disease using-soluble gpvi
RS63482B1 (sr) 2015-08-05 2022-09-30 Acticor Biotech Nova anti-humana gpvi antitela i njihove upotrebe
TWI866194B (zh) 2017-02-03 2024-12-11 法商艾提寇生物技術公司 使用抗人類ｇｐｖｉ抗體抑制血小板凝集
AU2019270342A1 (en) 2018-05-16 2020-10-29 Morphosys Ag Antibodies targeting glycoprotein VI
GB202020602D0 (en) * 2020-12-24 2021-02-10 Univ Birmingham Nanobody

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US20040001826A1 (en) * 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof

Also Published As

Publication number Publication date
GB0130543D0 (en) 2002-02-06
CA2510745A1 (en) 2003-07-03
DE60238556D1 (de) 2011-01-20
AU2002352438B2 (en) 2009-09-03
AU2002352438A1 (en) 2003-07-09
WO2003054020A3 (en) 2003-12-18
US20060088531A1 (en) 2006-04-27
EP1458759A2 (de) 2004-09-22
EP1458759B1 (de) 2010-12-08
WO2003054020A2 (en) 2003-07-03
US8853368B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
ATE490983T1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
IL299221A (en) Cd3 binding antibodies
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
ATE548386T1 (de) Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
AR035581A1 (es) Anticuerpos para il-1beta humana
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
NZ607711A (en) Antibodies directed to her-3 and uses thereof
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
WO2004016769A3 (en) Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
EP2796466A3 (de) Für IL-31 spezifische humanisierte Antikörpermoleküle
TW200716182A (en) Antibodies directed to CD20 and uses thereof
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
PE20080100A1 (es) ANTICUERPOS BLOQUEANTES DE LA FUNCION DE LA INTEGRINA a5ß1 HUMANOS Y HUMANIZADOS DE GRAN AFINIDAD CON INMUNOGENICIDAD REDUCIDA
DE60137202D1 (de) Scfv-moleküle gegen egfrviii mit verbesserter zytotoxizität und ausbeute, darauf basierte immuntoxine, und verfahren zur deren verwendung
CO5280086A1 (es) Molecula de enlace de cd154, construccion de adn, vector de expresion, composcion y combinacion farmaceutica
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
PE20230389A1 (es) Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
RU2014100111A (ru) МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
ES2570153T3 (es) Anticuerpos anti-C5aR con propiedades mejoradas
PE20020871A1 (es) Moleculas de enlace terapeuticas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties